AzTrials
AzTrials

ObesityChronoFastingNCT07759414

Chrono-Fasting in Overweight and Obese Adolescents

A study testing Early TRF and late TRF in people with Obesity, run by University of Thessaly at 1 site in Greece.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Childhood and adolescent obesity represents a major global public health concern, with a steadily increasing prevalence over recent decades, accompanied by a rise in metabolic disorders among younger populations. Read more about this study

Who is it for?
Ages 12 to 18 years
Conditions the study is for
Obesity
What is being tested?
Early TRF and late TRF
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteGreece
Study dates
Jan 2027to Sep 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Adolescents aged 12-18 years.
  • Screening for overweight/obesity, defined according to the World Health Organization (WHO) Growth Reference for School-aged Children and Adolescents (5-19 years) as a body mass index (BMI)-for-age z-score > +1 Standard Deviation (SD)
  • Late chronotype, assessed using the Morningness-Eveningness Questionnaire (rMEQ) in Greek language
  • Provision of verbal assent from the participants and written informed consent from participants and their parents/guardians.

Who cannot join

  • Early or intermediate chronotype, assessed using the rMEQ questionnaire in Greek language.
  • Presence of chronic medical conditions affecting metabolism (i.e., diabetes mellitus, thyroid disorders).
  • Use of medications that may influence body weight, appetite, or metabolism. (i.e. thyroxin or other thyroid medication, metformin, glpi1 analogs, estrogens, progesterone, testosterone, antidepressants)
  • Diagnosed eating disorders.
  • Participation in another clinical trial or structured weight loss program.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Nikolaos Ntelis Ioannis Nikolaos I. Ntelis, PhD candidate contact

+306981955467

delidiet.gr@gmail.com

Greece1 site
  • Private Endocrine Center

    Larissa, Thessaly

Other trials in Greece

About this study

Official title: CHRONOFASTING: The Role of Chronotype in Treatment of Overweight/Obesity in Adolescence: The Study Protocol for a Randomized Controlled Trial

Childhood and adolescent obesity represents a major global public health concern, with a steadily increasing prevalence over recent decades, accompanied by a rise in metabolic disorders among younger populations. Time-restricted feeding (TRF) has emerged as a promising dietary intervention, with preliminary evidence suggesting potential beneficial effects on body weight reduction and metabolic parameters in adolescents with overweight or obesity.

Chronotype, defined as an individual's sleeping habits and daily activities, has a biological basis and is influenced by the circadian rhythm. Chronotype is shaped by behavioral and environmental factors, including sleep schedules, meal timing, and light exposure, and plays an important role in regulating physiological processes. Notably, adolescents with a late chronotype are more likely to exhibit higher body mass index (BMI), irregular eating patterns, including breakfast skipping, and potentially reduced responsiveness to weight-loss interventions.

Read more

Despite the growing body of literature on TRF in adolescents, existing intervention models remain heterogeneous and do not account for chronotype as a potential modifier of treatment effectiveness. This represents an important gap in current research.

Therefore, investigating the interaction between chronotype and the timing of food intake within TRF regimens is of particular interest. Additionally, comparing different intervention strategies with a control group may provide more robust evidence regarding their relative effectiveness.

The aim of this randomized controlled trial is to evaluate the effectiveness of two TRF interventions combined with calorie restriction on weight loss in adolescents with overweight or obesity and a late chronotype, compared with a control group receiving calorie restriction without specific instructions regarding meal timing.

The primary outcome variable is the change in body weight z-score, measured at baseline, at week 4, week 8 and at the end of the intervention (week 12). Secondary outcomes include changes in fat mass (FM), fat-free mass (FFM), waist circumference (WC), waist-to-hip ratio (WHR), handgrip strength, and behavioral outcomes, including physical activity levels (PAL), quality of life (QoL), and changes in chronotype.

Intercurrent events, such as non-adherence to the intervention, will be handled using an intention-to-treat approach, including all randomized participants in the analysis.

All participants will be monitored throughout the study period. Adherence to the intervention protocols will be assessed through CGM system and via 24 hour dietary recalls and monitoring of eating windows. Participants will be instructed to record daily meal timing, and adherence will be evaluated based on consistency with the prescribed time-restricted feeding schedule. Continuous glucose monitoring will be performed during the first and last 14 days of the study. All participants in the groups will be monitored. All participants will receive a phone call assessment in week 6 to ensure adherence

Participation in this study may provide potential benefits, including weight loss, improved metabolic health, and increased awareness of healthy lifestyle behaviors. Additionally, this study may contribute to the development of more effective and personalized dietary interventions for adolescent obesity.

Potential risks are expected to be minimal and primarily related to TRF, including temporary hunger, fatigue, or mild discomfort, particularly during the initial adaptation period, as well as mild irritation associated with CGM sensor placement. These effects are anticipated to be transient and will be carefully monitored throughout the study..

Conditions
Obesity
Being tested
Early TRF, late TRF, Control
Keywords
chronotype, IF, TRF, TRE, Obesity, adolescents, weight management, intermittent fasting, CGM
Medical subject headings
Obesity, Intermittent Fasting

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Early TRFOther

    16 hour intermittent fasting mediterranean diet 80% of daily energy expenditure and meals are at 10:00 - 14:00 - 18:00

  • late TRFOther

    16 hour intermittent fasting mediterranean diet 80% of daily energy expenditure and meals are at 14:00 - 18:00 - 22:00

  • ControlOther

    No intervention

Study groups in NCT07759414
Study groupRoleWhat they receive
eTRFExperimentalSpecific time of feeding: first meal at 10:00 a.m. and the last meal at 6:00 p.m. with 20% calorie deficit based on each participant's estimated total energy expenditure (TEE).
Receives: Other: Early TRF
lTRFExperimentalSpecific time of feeding: first meal at 2:00 p.m. and the last meal at 10:00 p.m. with 20% calorie deficit based on each participant's estimated total energy expenditure (TEE).
Receives: Other: late TRF
ControlActive comparator20% calorie deficit based on each participant's estimated total energy expenditure (TEE) with no restrictions in feeding time.
Receives: Other: Control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Weight Z score

    the change in weight's-score. Body weight will be measured using a calibrated digital scale (TANITA BC 545N) under standardized conditions at baseline, at 4 weeks, at 8 weeks and at the end of the study (12 weeks). The standardized conditions are mentioned in supplemental file No 4.

    Measured: Baseline, week 4, week 8 and week 12

Secondary outcomes (5)
  1. Fat Mass (kg)

    Fat mass (kg) will be measured using a calibrated bioelectrical impedance analysis device (TANITA BC-545N) under standardized conditions at baseline, week 4, week 8, and at the end of the study (week 12). The standardized measurement procedures are described in Supplementary File 4.

    Measured: Baseline, week 4, week 8 and week 12

  2. FFM

    Free Fat mass (kg) will be measured using a calibrated bioelectrical impedance analysis device (TANITA BC-545N) under standardized conditions at baseline, week 4, week 8, and at the end of the study (week 12). The standardized measurement procedures are described in Supplementary File 4.

    Measured: Baseline, week 4, week 8 and week 12

  3. Waist Circumference (WC) (cm)

    WC will be measured using a non-elastic measuring tape according to standardized protocols. The standardized measurement procedures are described in Supplementary File 4.

    Measured: Baseline, week 4, week 8 and week 12

  4. Waist-to-Hip Ratio (WHR)

    Waist-to-hip ratio (WHR) will be calculated by dividing waist circumference (cm) by hip circumference (cm). The standardized measurement procedures are described in Supplementary File 4.

    Measured: Baseline, week 4, week 8 and week 12.

  5. HandGrip Strength (HS)

    Handgrip strength (HS) will be assessed using a calibrated hand dynamometer (Jamar J00105).

    Measured: Baseline, week 4, week 8 and week 12.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Aug 2026
  2. Study startJan 2027 (estimated)
  3. Primary completionSep 2028 (estimated)
  4. Study completionSep 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
three parallel groups: 2 interventional groups and 1 control group
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07759414
Sponsor's protocol ID
UTH-DND-2026-001
Other IDs
No Funding Number
Acronym
ChronoFasting
Status last verified
Jul 2026
First submitted
30 Jul 2026
Last updated
12 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Ekiz Erim S, Sert H. The relationship between chronotype and obesity: A systematic review. Chronobiol Int. 2023 Apr;40(4):529-541. doi: 10.1080/07420528.2023.2180385. Epub 2023 Feb 20.

    PubMed 36803075
  • Moon S, Kang J, Kim SH, Chung HS, Kim YJ, Yu JM, Cho ST, Oh CM, Kim T. Beneficial Effects of Time-Restricted Eating on Metabolic Diseases: A Systemic Review and Meta-Analysis. Nutrients. 2020 Apr 29;12(5):1267. doi: 10.3390/nu12051267.

    PubMed 32365676
  • Ribas-Latre A, Fernandez-Veledo S, Vendrell J. Time-restricted eating, the clock ticking behind the scenes. Front Pharmacol. 2024 Aug 8;15:1428601. doi: 10.3389/fphar.2024.1428601. eCollection 2024.

    PubMed 39175542

Questions about this trial

What is this clinical trial studying?

A study testing Early TRF and late TRF in people with Obesity, run by University of Thessaly at 1 site in Greece.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Nikolaos Ntelis Ioannis Nikolaos I. Ntelis, PhD candidate (+306981955467, delidiet.gr@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Weight Z score (time frame: Baseline, week 4, week 8 and week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07759414, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in